JPH08505130A - 認識障害の治療のためのフエンセリンの使用 - Google Patents
認識障害の治療のためのフエンセリンの使用Info
- Publication number
- JPH08505130A JPH08505130A JP6513358A JP51335894A JPH08505130A JP H08505130 A JPH08505130 A JP H08505130A JP 6513358 A JP6513358 A JP 6513358A JP 51335894 A JP51335894 A JP 51335894A JP H08505130 A JPH08505130 A JP H08505130A
- Authority
- JP
- Japan
- Prior art keywords
- phenserine
- group
- maze
- scop
- phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.有効量のフェンセリンまたはその薬理学的に許容できる塩を患者に投 与することからなる、老化またはアルツハイマー症による認識障害のコリン作用 治療をする方法。 2.薬理学的に許容できる塩が、酒石酸塩、燐酸塩およびフマル酸塩から なる群より選ばれたものである請求項1の方法。 3.有効量範囲が患者の体重1kg当たり0.001グラムから1グラムであ る請求項1の方法。 4.コリン作用上有効量のフェンセリンまたはフェンセリンの薬理学的に 許容できる塩と薬理学的に許容できる担体または賦形剤よりなる医薬組成物。 5.薬理学的に許容できる塩が、(−)−N−フェニル−カルバモイルエ セロリンの酒石酸塩、燐酸塩およびフマル酸塩からなる群より選ばれたものであ る請求項4の医薬組成物。 6.担体または賦形剤がフェンセリンまたはその塩を約0.001重量%から1 .0重量%含んでなる請求項4の医薬組成物。 7.薬効成分として有効量のフェンセリンまたはその薬理学的に許容でき る塩からなる医薬組成物を患者に投与することからなる、ヒトのアルツハイマー 症の治療方法。 8.薬理学的に許容できる塩が、酒石酸塩、燐酸塩およびフマル酸塩から なる群より選ばれたものである請求項7の方法。 9.有効量範囲が患者の体重1kg当たり0.001グラムから1グラムであ る請求項8の方法。 10.酒石酸塩、燐酸塩およびフマル酸塩からなる群より選ばれた、(− )−N−フェニルカルバモイル エセロリンの薬理学的に許容できる塩。 11.(−)−N−フェニル−カルバモイル エセロリンの燐酸塩。 12.(−)−N−フェニル−カルバモイル エセロリンの酒石酸塩。 13.(−)−N−フェニル−カルバモイル エセロリンのフマル酸塩。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/980,399 US5409948A (en) | 1992-11-23 | 1992-11-23 | Method for treating cognitive disorders with phenserine |
US07/980,399 | 1992-11-23 | ||
PCT/US1993/011423 WO1994012176A1 (en) | 1992-11-23 | 1993-11-23 | Use of phenserine to treat cognitive disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08505130A true JPH08505130A (ja) | 1996-06-04 |
JP3778363B2 JP3778363B2 (ja) | 2006-05-24 |
Family
ID=25527533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51335894A Expired - Fee Related JP3778363B2 (ja) | 1992-11-23 | 1993-11-23 | 哺乳動物における加齢またはアルツハイマー症に関連する認識障害の治療のための医薬 |
Country Status (11)
Country | Link |
---|---|
US (1) | US5409948A (ja) |
EP (1) | EP0668763B1 (ja) |
JP (1) | JP3778363B2 (ja) |
AT (1) | ATE213411T1 (ja) |
AU (1) | AU693428B2 (ja) |
CA (1) | CA2149924C (ja) |
DE (1) | DE69331605T2 (ja) |
DK (1) | DK0668763T3 (ja) |
ES (1) | ES2173111T3 (ja) |
PT (1) | PT668763E (ja) |
WO (1) | WO1994012176A1 (ja) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2264750C (en) * | 1997-07-09 | 2009-06-16 | Nigel H. Greig | Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias |
US20030125609A1 (en) * | 2001-08-03 | 2003-07-03 | Robert Becker | Method for reliable measurement in medical care and patient self monitoring |
US6495700B1 (en) | 2002-01-09 | 2002-12-17 | Axonyx, Inc. | Process for producing phenserine and its analog |
US7612078B2 (en) | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
WO2005042475A2 (en) * | 2003-10-21 | 2005-05-12 | Sention, Inc. | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents |
US20050182044A1 (en) * | 2004-02-17 | 2005-08-18 | Bruinsma Gosse B. | Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate |
WO2005089746A1 (en) * | 2004-03-19 | 2005-09-29 | Axonyx, Inc. | Dosage titration for treatment of cognitive disorders |
US20070213388A1 (en) * | 2004-03-19 | 2007-09-13 | Bruinsma Gosse B | Acetylcholinesterase Inhibitors and N-Methyl-D-Aspartate Antagonists Useful in the Treatment of of Cognitive Disorders |
US7488736B2 (en) | 2004-05-17 | 2009-02-10 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
CA2508585A1 (en) * | 2004-06-01 | 2005-12-01 | Axonyx, Inc. | Transdermal delivery system for treatment of cognitive disorders |
WO2005123068A2 (en) * | 2004-06-08 | 2005-12-29 | Axonyx, Inc. | Methods of dealying alzheimer’s disease progression using a beta-amyloid precursor protein inhibitor and a hmg coa reductase inhibitor |
US7598265B2 (en) * | 2004-09-30 | 2009-10-06 | Epix Delaware, Inc. | Compositions and methods for treating CNS disorders |
US7407966B2 (en) | 2004-10-07 | 2008-08-05 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
US7576211B2 (en) | 2004-09-30 | 2009-08-18 | Epix Delaware, Inc. | Synthesis of thienopyridinone compounds and related intermediates |
US20060194723A1 (en) * | 2005-02-28 | 2006-08-31 | Rabinoff Michael D | Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement |
WO2006138385A2 (en) * | 2005-06-14 | 2006-12-28 | Cancog Technologies Inc.24 | Use of phenserine and analogs to treat behavioral problems and improve trainability |
MX2009008288A (es) * | 2007-02-02 | 2009-12-01 | Colucid Pharmaceuticals Inc | Compuestos que inhiben la colinesterasa. |
RU2327480C1 (ru) | 2007-05-23 | 2008-06-27 | Виктор Иванович Рощин | Активный ингредиент лекарственного средства, лекарственное средство, фармацевтическая композиция и способ лечения больных с дементным синдромом |
WO2009011901A2 (en) * | 2007-07-18 | 2009-01-22 | Colucid Pharmaceuticals, Inc. | Methods for promoting wakefulness |
US8593728B2 (en) * | 2009-02-19 | 2013-11-26 | Toyota Motor Engineering & Manufacturing North America, Inc. | Multilayer photonic structures |
US8114894B2 (en) | 2008-12-03 | 2012-02-14 | Nanotherapeutics, Inc. | Bicyclic compounds and methods of making and using same |
PT2453890T (pt) * | 2009-07-17 | 2020-08-25 | Allergan Inc | Composições compreendendo um inibidor de colinesterase para tratar perturbações cognitivas |
US20120225922A1 (en) * | 2011-03-04 | 2012-09-06 | Qr Pharma | Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration |
AU2016309815B2 (en) | 2015-08-14 | 2022-04-07 | Annovis Bio, Inc. | Methods of treatment or prevention of acute brain or nerve injuries |
US10864192B2 (en) | 2016-01-15 | 2020-12-15 | Aristea Translational Medicine Corporation | Compositions and methods for inhibiting brain trauma-induced neurodegeneration and related conditions |
US10111860B1 (en) | 2016-01-15 | 2018-10-30 | Aristea Translational Medicine Corporation | Compositions and methods for treating concussion |
CA3083015A1 (en) | 2017-05-24 | 2018-11-28 | Qr Pharma, Inc. | Prevention or treatment of disease states due to metal dis-homeostasis via administration of posiphen to healthy or sick humans |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US479107A (en) * | 1892-07-19 | oesterreich | ||
US4791107A (en) * | 1986-07-16 | 1988-12-13 | Hoechst-Roussel Pharmaceuticals, Inc. | Memory enhancing and analgesic 1,2,3,3A,8,8A-hexahydro-3A,8 (and) 1,3A,8)-di(and tri)methylpyrrolo(2,3-B)indoles, compositions and use |
DE3843239C1 (ja) * | 1988-12-22 | 1990-02-22 | Lohmann Therapie Syst Lts | |
US4971992A (en) * | 1989-03-27 | 1990-11-20 | Hoechst-Roussel Pharmaceuticals Inc. | Carbonate derivatives of eseroline |
US4996201A (en) * | 1989-08-02 | 1991-02-26 | Warner-Lambert Co. | 4-(N-substituted amino)-2-butynyl-1-carbamates and thiocarbamates and derivatives thereof as centrally acting muscarinic agents |
US4914102A (en) * | 1989-09-28 | 1990-04-03 | Hoechst Roussel Pharmaceuticals, Inc. | N-aminocarbamates related to physostigmine, pharmacentical compositions and use |
US5077289A (en) * | 1989-11-30 | 1991-12-31 | Hoechst Roussel Pharmaceuticals Inc. | Memory enhancing and analgesic aminocarbonylcarbamates related to physostigmine |
US5171750A (en) * | 1991-09-26 | 1992-12-15 | The United States Of America As Represented By The Department Of Health And Human Services | Substituted phenserines as specific inhibitors of acetylcholinesterase |
-
1992
- 1992-11-23 US US07/980,399 patent/US5409948A/en not_active Expired - Lifetime
-
1993
- 1993-11-23 JP JP51335894A patent/JP3778363B2/ja not_active Expired - Fee Related
- 1993-11-23 DK DK94903295T patent/DK0668763T3/da active
- 1993-11-23 ES ES94903295T patent/ES2173111T3/es not_active Expired - Lifetime
- 1993-11-23 AU AU57290/94A patent/AU693428B2/en not_active Ceased
- 1993-11-23 DE DE69331605T patent/DE69331605T2/de not_active Expired - Fee Related
- 1993-11-23 EP EP94903295A patent/EP0668763B1/en not_active Expired - Lifetime
- 1993-11-23 CA CA002149924A patent/CA2149924C/en not_active Expired - Fee Related
- 1993-11-23 PT PT94903295T patent/PT668763E/pt unknown
- 1993-11-23 AT AT94903295T patent/ATE213411T1/de not_active IP Right Cessation
- 1993-11-23 WO PCT/US1993/011423 patent/WO1994012176A1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
DE69331605T2 (de) | 2002-10-31 |
DK0668763T3 (da) | 2002-06-03 |
AU5729094A (en) | 1994-06-22 |
ATE213411T1 (de) | 2002-03-15 |
AU693428B2 (en) | 1998-07-02 |
WO1994012176A1 (en) | 1994-06-09 |
JP3778363B2 (ja) | 2006-05-24 |
DE69331605D1 (de) | 2002-03-28 |
ES2173111T3 (es) | 2002-10-16 |
CA2149924A1 (en) | 1994-06-09 |
US5409948A (en) | 1995-04-25 |
CA2149924C (en) | 2006-01-31 |
EP0668763B1 (en) | 2002-02-20 |
EP0668763A1 (en) | 1995-08-30 |
PT668763E (pt) | 2002-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08505130A (ja) | 認識障害の治療のためのフエンセリンの使用 | |
DE69832688T2 (de) | Hochselektive butyrylcholinesterase inhibitoren zur behandlung und zur diagnose von demenz und alzheimers krankheit | |
US20220265685A1 (en) | Methods and compositions for improving cognitive function | |
US5962535A (en) | Composition for alzheimer's disease | |
AU2009324495B2 (en) | Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles | |
JP6808679B2 (ja) | 認知機能を改善するための方法および組成物 | |
US20220249483A1 (en) | Compositions and methods for treatment of fragile x syndrome | |
CN110913851A (zh) | 治疗外伤性脑损伤的组合物和方法 | |
MXPA00012248A (es) | Incrementadores de acetilcolina. | |
Riekkinen et al. | Effects of combined chronic nimodipine and acute metrifonate treatment on spatial and avoidance behavior | |
US20070167509A1 (en) | Use of phenserine and analogs to treat behavioral problems and improve trainability | |
EP0952826B1 (en) | Idebenone containing combination agent for treating alzheimer's disease | |
US20210379061A1 (en) | Balipodect for treating or preventing autism spectrum disorders | |
CA2724386A1 (en) | Methods and compositions for improving cognitive function | |
US20230390232A1 (en) | N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating the pathogenesis of neurodegenerative disorders | |
US20030087959A1 (en) | Methods of attenuating cognitive deficits with sulfonyl fluorides | |
EA043008B1 (ru) | Комбинации эдаравона для лечения ишемических повреждений мозга | |
CA2527566A1 (en) | Use of phenserine to treat cognitive disorders | |
Khoja | Preclinical investigation of ivermectin as a novel therapeutic agent for treatment of alcohol use disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040212 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20040520 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20040527 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060126 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060223 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |